r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

LR

Laurence Reid

Insider · Director · MGX

Laurence Reid files insider transactions with the SEC as a director of Metagenomi. We hold 1 disclosed purchase or sale filed since 3 June 2010, 1 of them in the last 90 days.

  • Files for 4 companiesMGX, KALV, DBTX, ALNY
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure11 September 2026

Positions held

4 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 2 September 2025 — 9 September 2026Director · Metagenomi 4 Form 4 lines · source: SEC Form 4
  • Filed 23 November 2024 — 11 June 2026Director · KalVista Pharmaceuticals 2 Form 4 lines · source: SEC Form 4
  • Filed 15 September 2021 — 25 September 2023Director and Officer · Decibel Therapeutics 8 Form 4 lines · source: SEC Form 4
  • Filed 1 June 2010 — 31 December 2014SVP, Chief Business Officer · Alnylam Pharmaceuticals 54 Form 4 lines · source: SEC Form 4

Every transaction

68 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
68 of 68 shown
9 Sep 202611 Sep 2026SEC Form 42 dbought on the open marketMetagenomi Therapeutics19,883 sharesup +0.9%up +0.0%
9 Sep 202611 Sep 2026SEC Form 42 dbought on the open marketMetagenomi Therapeutics117 sharesup +0.9%up +0.0%
11 Jun 202611 Jun 2026SEC Form 40 dreturned to the issuernot a tradeKALVKalVista Pharmaceuticalsderivative17,000 shares——
9 Jun 202611 Jun 2026SEC Form 42 dwas grantednot a tradeMetagenomi Therapeuticsderivative17,400 sharesdown −5.7%down −7.2%
2 Sep 20252 Sep 2025SEC Form 40 dwas grantednot a tradeMetagenomiderivative42,000 sharesdown −36.3%down −36.3%
23 Nov 202426 Nov 2024SEC Form 43 dwas grantednot a tradeKALVKalVista Pharmaceuticalsderivative17,000 shares——
25 Sep 202325 Sep 2023SEC Form 40 dreturned to the issuernot a tradeDBTXDecibel Therapeuticsderivative187,500 shares——
25 Sep 202325 Sep 2023SEC Form 40 dreturned to the issuernot a tradeDBTXDecibel Therapeuticsderivative72,000 shares——
25 Sep 202325 Sep 2023SEC Form 40 dreturned to the issuernot a tradeDBTXDecibel Therapeuticsderivative1,072,539 shares——
25 Sep 202325 Sep 2023SEC Form 40 dreturned to the issuernot a tradeDBTXDecibel Therapeutics220,849 shares——
16 Mar 202317 Mar 2023SEC Form 41 dwas grantednot a tradeDBTXDecibel Therapeuticsderivative72,000 shares——
16 Mar 202317 Mar 2023SEC Form 41 dwas grantednot a tradeDBTXDecibel Therapeutics195,000 shares——
25 Feb 202228 Feb 2022SEC Form 43 dwas grantednot a tradeDBTXDecibel Therapeuticsderivative187,500 shares——
15 Sep 202117 Sep 2021SEC Form 42 dbought on the open marketDBTXDecibel Therapeutics10,000 shares——
31 Dec 20145 Jan 2015SEC Form 45 dexercised options overnot a tradeAlnylam Pharmaceuticals17,000 sharesup +156.4%up +160.7%
31 Dec 20145 Jan 2015SEC Form 45 dhad shares withheld for taxnot a tradeAlnylam Pharmaceuticals2,802 sharesup +156.4%up +160.7%
31 Dec 20145 Jan 2015SEC Form 45 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative17,000 sharesup +156.4%up +160.7%
12 Dec 201416 Dec 2014SEC Form 44 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative6,667 sharesup +147.6%up +170.1%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticals2,500 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticals3,861 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticals3,639 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals5,413 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals4,485 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals102 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative2,500 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative3,861 sharesup +176.5%up +177.6%
18 Nov 201419 Nov 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative3,639 sharesup +176.5%up +177.6%
18 Aug 201420 Aug 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals2,500 sharesup +269.9%up +269.3%
18 Aug 201420 Aug 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals11,000 sharesup +269.9%up +269.3%
18 Aug 201420 Aug 2014SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals6,500 sharesup +269.9%up +269.3%
18 Aug 201420 Aug 2014SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals7,000 sharesup +269.9%up +269.3%
18 Aug 201420 Aug 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative2,500 sharesup +269.9%up +269.3%
18 Aug 201420 Aug 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative11,000 sharesup +269.9%up +269.3%
19 May 201421 May 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals2,500 sharesup +326.8%up +367.7%
19 May 201421 May 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals11,000 sharesup +326.8%up +367.7%
19 May 201421 May 2014SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals2,600 sharesup +326.8%up +367.7%
19 May 201421 May 2014SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals10,900 sharesup +326.8%up +367.7%
19 May 201421 May 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative2,500 sharesup +326.8%up +367.7%
19 May 201421 May 2014SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative11,000 sharesup +326.8%up +367.7%
19 Feb 201420 Feb 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticals10,000 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticals3,500 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals3,079 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals11,465 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals5,456 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dsold on the open marketAlnylam Pharmaceuticals400 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative10,000 sharesup +214.2%up +193.6%
19 Feb 201420 Feb 2014SEC Form 41 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative3,500 sharesup +214.2%up +193.6%
23 Jan 201427 Jan 2014SEC Form 44 dhad shares withheld for taxnot a tradeAlnylam Pharmaceuticals3,698 sharesup +177.9%up +206.8%
30 Dec 20132 Jan 2014SEC Form 43 dexercised options overnot a tradeAlnylam Pharmaceuticals3,752 sharesup +285.5%up +289.4%
30 Dec 20132 Jan 2014SEC Form 43 dhad shares withheld for taxnot a tradeAlnylam Pharmaceuticals930 sharesup +285.5%up +289.4%
30 Dec 20132 Jan 2014SEC Form 43 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative3,752 sharesup +285.5%up +289.4%
18 Dec 201318 Dec 2013SEC Form 40 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative20,000 sharesup +294.7%up +294.7%
13 Nov 201315 Nov 2013SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative13,500 sharesup +367.7%up +360.9%
13 Nov 201315 Nov 2013SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals13,500 sharesup +367.7%up +360.9%
13 Nov 201315 Nov 2013SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals13,500 sharesup +367.7%up +360.9%
28 May 201330 May 2013SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative5,000 sharesup +733.9%up +725.1%
28 May 201330 May 2013SEC Form 42 dexercised options overnot a tradeAlnylam Pharmaceuticals5,000 sharesup +733.9%up +725.1%
28 May 201330 May 2013SEC Form 42 dsold on the open marketAlnylam Pharmaceuticals5,000 sharesup +733.9%up +725.1%
8 Feb 201312 Feb 2013SEC Form 44 dexercised options overnot a tradeAlnylam Pharmaceuticals5,000 sharesup +901.9%up +923.0%
8 Feb 201312 Feb 2013SEC Form 44 dsold on the open marketAlnylam Pharmaceuticals5,000 sharesup +901.9%up +923.0%
8 Feb 201312 Feb 2013SEC Form 44 dexercised options overnot a tradeAlnylam Pharmaceuticalsderivative5,000 sharesup +901.9%up +923.0%
20 Dec 201221 Dec 2012SEC Form 41 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative40,000 sharesup +1232.7%up +1276.2%
21 Feb 201223 Feb 2012SEC Form 42 dbought on the open marketAlnylam Pharmaceuticals930 sharesup +1975.8%up +1848.9%
23 Jan 201225 Jan 2012SEC Form 42 dwas grantednot a tradeAlnylam Pharmaceuticals10,751 sharesup +2268.4%up +2183.6%
30 Nov 20112 Dec 2011SEC Form 42 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative40,000 sharesup +3402.5%up +3551.7%
8 Dec 201010 Dec 2010SEC Form 42 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative27,589 sharesup +2620.8%up +2526.0%
11 Jun 201015 Jun 2010SEC Form 44 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative175,000 sharesup +1455.2%up +1456.2%
1 Jun 20103 Jun 2010SEC Form 42 dwas grantednot a tradeAlnylam Pharmaceuticalsderivative175,000 sharesup +1514.8%up +1445.6%

Both percentages are the stock’s move, not Laurence Reid’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 58 of the 68 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.